£1.3 billion industry/government investment in UK announced under second life sciences sector deal

The second Life Sciences Sector Deal will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s modern Industrial Strategy.

  • life-saving early disease detection technology to be developed by new partnership between government and industry using artificial intelligence (AI) to develop the next generation of treatments, including a first-of-its-kind national health programme
  • the second Life Sciences Sector Deal, with industry investment from 10 companies, will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s modern Industrial Strategy
  • the deal signals a vote of confidence in UK industry, with global biopharmaceutical company UCB investing around £1 billion in research and development, including in a new state-of-the-art facility

In Manchester, healthcare company Roche, will invest £20 million investment over three years in a precision cancer research partnership with the Christie NHS Foundation Trust in Manchester. This will use cutting-edge genomic technology and big data to accelerate the next generation of digital clinical trials for rare cancers, making the UK a leading global hub for rare cancer trials, potentially benefiting nearly 5,000 patients annually.

Commenting on the news, Prof Ben Bridgewater, Chief Executive of Health Innovation Manchester, said: “The news further cements Manchester’s position as being at the leading edge of precision healthcare and is fast becoming a global life sciences cluster.  This is further enhanced by devolution and our strong expertise in tech, digital and data sciences.”

Read the full release on the Gov.uk website